Investors in Align Technology
1. Teen population
Align's Invisalign system helps treat malocclusion (misaligned teeth) using plastic orthodontic aligners. The company touts several benefits that Invisalign offers compared with braces, including near-invisibility, comfort, and easier dental hygiene.
As you might expect, the teen market helped drive Align's growth in recent years. Most of the company's sales are generated from North America, Europe, and Japan. Why stop at the developed nations? Align isn't.
The company has taken steps to expand globally beyond its core markets. In 2011, Align launched Invisalign in several of the largest cities in China. It also has distribution partners in other emerging markets, including Latin America and Russia.
What does the potential teen market look like for the less developed nations?
Source: United Nations Population Division data and author extrapolations.
Despite a plateau beginning after 2005, the growth in the less developed world's teen population should resume a nice uptrend within a few years. That could present great opportunities for Align down the road.
There is a bit of good news for developed nations as well. While the teen population in these countries has declined over the past decade, UN data shows that increasing birth rates in recent years should lead to a rebound in the near future.
2. Trained doctors
Since only trained doctors can provide Invisalign to patients, Align's fortunes depend on how many professionals know how to follow the process. With greater growth prospects in international markets, training dentists and orthodontists in other countries is important. How do things look on this front?
Source: Company 10-K reports.
Align Technology has seen steady growth in the number of trained international professionals in the past three years. The temporary slower increase in 2011 resulted from delaying training while the rollout of the new Invisalign G3 product was completed.
Another positive trend is a slight increase in the average number of cases that each doctor purchases from Align. More doctors times more products shipped per doctor equals more good news for the company.
3. Free cash flow
Here's a look at the trend for Align's free cash flow on a trailing-12-month basis.
Everything looks great through 2011, but then free cash flow starts falling. That can't be good, right? Actually, it can.
The primary reason for the decline is Align's acquisition of Cadent in 2011. Cadent makes 3-D digital scanning solutions for orthodontics and dentistry. A doctor who uses Cadent's intra-oral scanner can make digital scans of a patient's mouth and send the scan electronically to Align. Align then uses the 3-D scan to rapidly manufacture custom aligners specifically for the patient. The older method required the doctor to make a polyvinyl-siloxane impression of the patient's mouth and ship the physical impression to Align.
Cadent looks like a good fit. My view is that this acquisition will prove to be a big positive for Align over the long run.
Not every line is good news for Align. Fellow Fool Seth Jayson makes a solid argument in a recent article on why the company's earnings aren't as good as they might seem. The lineup of rivals looks tough as well.
Then there's the complex relationship with Danaher
Several trends appear to be in Align's favor. Should investors buy now?
The stock seems to be priced highly, with a trailing P/E of 32. This multiple is significantly higher than the values for any of the competitors mentioned here. It might be best to wait for a pullback before buying. After all, the most important line is your bottom line.
Fool contributor Keith Speights owns no shares in the stocks mentioned above. Motley Fool newsletter services have recommended buying shares of 3M and creating a diagonal call position in 3M. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Healthcare Stocks to Buy Right Now
The S&P 500's top-performing stock last year and two under-the-radar small caps could be worth a closer look.
Why This Top S&P 500 Stock Tumbled 14.8% in December
One of the S&P 500's best-performing stocks in 2017 dropped by double digits last month.
Why I Just Bought the Best-Performing S&P 500 Stock of 2017
I was late to the party with Align Technology. But not too late.